Oncologist counseling practice and COVID‐19 vaccination outcomes for patients with history of PEG‐asparaginase hypersensitivity

Zarnegar‐Lumley, S., Stone, C.A., Smith, C.M., Hall, L.L., Luck, K.E., Koo, G., Plager, J.H., Phillips, E.J. and Friedman, D.L. (2022) Oncologist counseling practice and COVID‐19 vaccination outcomes for patients with history of PEG‐asparaginase hypersensitivity. Pediatric Blood & Cancer . Early View.

Abstract

Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an effective strategy to prevent serious coronavirus disease 2019 (COVID-19) and is important for oncology patients. mRNA-based COVID-19 vaccines are contraindicated in those with a history of severe or immediate allergy to any vaccine component, including polyethylene glycol (PEG)2000. Patients with acute lymphoblastic leukemia/lymphoma receive asparaginase conjugated to PEG5000 (PEG-ASNase) and those with PEG-ASNase-associated hypersensitivity may be unnecessarily excluded from receiving mRNA COVID-19 vaccines. We, therefore, surveyed oncologists on COVID-19 vaccine counseling practice and vaccination outcomes in COVID-19 vaccination-eligible patients and show safe receipt of mRNA vaccines despite PEG-ASNase hypersensitivity

Item Type:	Journal Article
Murdoch Affiliation(s):	Institute for Immunology and Infectious Diseases
Publisher:	Wiley
Copyright:	© 2022 Wiley Periodicals LLC
URI:	http://researchrepository.murdoch.edu.au/id/eprint/64517

Item Control Page